An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spruce Biosciences (Nasdaq: SPRB) is set to present baseline characteristics of its CAHmelia program at the Pediatric Endocrine Society 2024 Annual Meeting, highlighting tildacerfont in adult congenital adrenal hyperplasia management. The presentation aims to address unmet medical needs in pediatric CAH.
Spruce Biosciences (Nasdaq: SPRB) presenterà le caratteristiche di base del suo programma CAHmelia durante l'incontro annuale 2024 della Società Pediatrica di Endocrinologia, evidenziando l'uso di tildacerfont nella gestione dell'iperplasia surrenale congenita negli adulti. La presentazione mira a rispondere alle esigenze mediche insoddisfatte nella CAH pediatrica.
Spruce Biosciences (Nasdaq: SPRB) presentará las características basales de su programa CAHmelia en la Reunión Anual 2024 de la Sociedad de Endocrinología Pediátrica, destacando el tildacerfont en el manejo de la hiperplasia suprarrenal congénita en adultos. La presentación tiene como objetivo abordar las necesidades médicas no cubiertas en la CAH pediátrica.
Spruce Biosciences (Nasdaq: SPRB)는 2024년 소아 내분비 학회 연례 회의에서 성인 선천성 부신 과형성 관리를 위한 틸다서폰트의 특성을 강조하는 CAHmelia 프로그램의 기초 특성을 발표할 예정입니다. 이 발표는 소아 CAH의 충족되지 않은 의료 요구를 다루는 것을 목표로 합니다.
Spruce Biosciences (Nasdaq: SPRB) présentera les caractéristiques de base de son programme CAHmelia lors de la réunion annuelle 2024 de la Société de Endocrinologie Pédiatrique, mettant en avant le tildacerfont dans la gestion de l'hyperplasie surrénalienne congénitale chez l'adulte. La présentation vise à répondre aux besoins médicaux non satisfaits dans la CAH pédiatrique.
Spruce Biosciences (Nasdaq: SPRB) wird die Grundcharakteristiken seines CAHmelia-Programms auf der Jahrestagung 2024 der Gesellschaft für Kinderendokrinologie vorstellen, wobei Tildacerfont in der Behandlung der angeborenen Nebennierenhyperplasie bei Erwachsenen hervorgehoben wird. Die Präsentation zielt darauf ab, ungedeckte medizinische Bedürfnisse bei pädiatrischer CAH anzusprechen.
Positive
None.
Negative
None.
Presentation to highlight baseline characteristics of Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.
In the poster presentation, Paul Thornton, M.B.B.S., will highlight baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management.
PES 2024 Presentation Details:
Title: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia
Abstract Number: 6898
Poster Session: 2
Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT
Presenter: Paul Thornton, M.B.B.S., Principal Investigator and Medical Director of the Endocrine and Diabetes Program at a CAH Center of Excellence
The poster will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.
What is Spruce Biosciences presenting at the Pediatric Endocrine Society 2024 Annual Meeting?
Spruce Biosciences is presenting baseline characteristics of its CAHmelia program at the Pediatric Endocrine Society 2024 Annual Meeting, focusing on tildacerfont in adult congenital adrenal hyperplasia.
When and where will the Pediatric Endocrine Society 2024 Annual Meeting take place?
The Pediatric Endocrine Society 2024 Annual Meeting will take place on May 2-5, 2024, in Chicago, IL.
Who will be the presenter at the poster presentation?
Paul Thornton, M.B.B.S., the Principal Investigator and Medical Director of the Endocrine and Diabetes Program at a CAH Center of Excellence, will be the presenter at the poster presentation.
What is the abstract number for the presentation?
The abstract number for the presentation is 6898.
When will the poster be available on Spruce Biosciences' website?
The poster will be available on the company's website starting May 3, 2024, at 12:15 p.m. CT.
spruce biosciences is a clinical stage biopharmaceutical company focused on developing novel therapies for rare diseases affecting the endocrine system.
